170730-06-0Relevant articles and documents
Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof
-
, (2020/12/14)
The invention provides a vascular endothelial growth factor receptor inhibitor and a preparation method and application thereof, and relates to a quinoline or quinazoline derivative with a structure as shown in a formula (I), a pharmaceutical composition containing a compound as shown in the formula (I) and application of the compound in preparation of drugs for preventing or treating angiogenesis-related diseases, in particular to prevention or treatment of tumors related to protein tyrosine kinase. Each substituent in the formula (I) is the same as the definition in the specification.
The selective 5-HT(1B) receptor inverse agonist 1-methyl-5-[[2'-methyl- 4'(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7- tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function bo
Gaster, Laramie M.,Blaney, Frank E.,Davies, Susannah,Duckworth, D. Malcolm,Ham, Peter,Jenkins, Sarah,Jennings, Andrew J.,Joiner, Graham F.,King, Frank D.,Mulholland, Keith R.,Wyman, Paul A.,Hagan, Jim J.,Hatcher, Jon,Jones, Brian J.,Middlemiss, Derek N.,Price, Gary W.,Riley, Graham,Roberts, Claire,Routledge, Carol,Selkirk, Julie,Slade, Paula D.
, p. 1218 - 1235 (2007/10/03)
5-HT1 receptors are members of the G-protein-coupled receptor superfamily and are negatively linked to adenylyl cyclase activity. The human 5-HT(1B) and 5-HT(1D) receptors (previously known as 5-HT(1Dβ) and 5- HT(1Dα), respectively), although e